Compare ORRF & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORRF | DRUG |
|---|---|---|
| Founded | 1919 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 692.0M | 707.1M |
| IPO Year | 1995 | 2020 |
| Metric | ORRF | DRUG |
|---|---|---|
| Price | $35.01 | $70.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $42.00 | ★ $124.00 |
| AVG Volume (30 Days) | ★ 157.0K | 93.1K |
| Earning Date | 04-21-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.40% | N/A |
| EPS Growth | ★ 182.43 | N/A |
| EPS | ★ 4.18 | N/A |
| Revenue | ★ $37,144,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.08 | N/A |
| P/E Ratio | $8.46 | ★ N/A |
| Revenue Growth | ★ 36.00 | N/A |
| 52 Week Low | $25.57 | $23.18 |
| 52 Week High | $40.72 | $123.75 |
| Indicator | ORRF | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 44.77 | 39.49 |
| Support Level | $34.51 | $49.47 |
| Resistance Level | $35.28 | $84.29 |
| Average True Range (ATR) | 0.99 | 3.95 |
| MACD | 0.13 | -0.06 |
| Stochastic Oscillator | 59.17 | 9.69 |
Orrstown Financial Services Inc is a financial holding company. Through its subsidiaries, it operates in the community banking segment and engages in lending activities, including commercial, residential, commercial mortgages, construction, municipal, and various forms of consumer lending and deposit services, including checking, savings, time, and money market deposits. The Group also provides fiduciary, investment advisory, insurance, and brokerage services. It offers services to individuals, professionals, small businesses, and other enterprises across different locations in the United States through its branch network and client service centers.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.